1525 O'Brien Drive
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
CEO: Bob Ragusa
91 articles with GRAIL, LLC
Backed by Amazon and Big Names Like Bristol-Myers Squibb, Celgene and Merck & Co., Bay Area's GRAIL Banks $900 Million
Bristol-Myers Squibb Release: Investment And Planned Collaboration With GRAIL On Blood-Based Cancer Screening
What You Need to Know About GRAIL
Why I'm Wary Of GRAIL And Its Plan To Develop A Cancer Blood Test
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
Illumina-Backed GRAIL Eyes $1 Billion Funding Round for Cancer DNA Test
GRAIL Announces Circulating Cell-free Genome Atlas (CCGA) Study As Foundation For Development Of Blood Test To Detect Cancer Early
Illumina's GRAIL and the $200 Billion Market They are Eyeing
Grail CEO Jeff Huber Driven By Personal Tragedy to Develop Early Cancer Screening Technology
Former Google Exec to Take Helm at San Francisco Diagnostic Firm Grail
Illumina Forms New Company GRAIL to Enable Early Cancer Detection via Blood-Based Screening